Longeveron (NASDAQ:LGVN) & CureVac (NASDAQ:CVAC) Head to Head Contrast

CureVac (NASDAQ:CVAC) and Longeveron (NASDAQ:LGVN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, dividends and earnings.

Valuation and Earnings

This table compares CureVac and Longeveron”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74 million	14.78	$175.50 million	$0.72	6.47
Longeveron	$1.20 million	6.86	-$22.70 million	($9.90)	-0.26

CureVac has higher revenue and earnings than Longeveron. Longeveron is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500.

Insider and Institutional Ownership

17.3% of CureVac shares are owned by institutional investors. Comparatively, 10.0% of Longeveron shares are owned by institutional investors. 2.1% of CureVac shares are owned by insiders. Comparatively, 7.4% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CureVac and Longeveron, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1	0	0	0	1.00
Longeveron	1	1	1	0	2.00

Longeveron has a consensus price target of $80.00, suggesting a potential upside of 3,000.78%. Given Longeveron’s stronger consensus rating and higher probable upside, analysts clearly believe Longeveron is more favorable than CureVac.

Profitability

This table compares CureVac and Longeveron’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Longeveron	-1,977.59%	-223.19%	-150.20%

Summary

CureVac beats Longeveron on 10 of the 14 factors compared between the two stocks.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

About Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.